Economic impact of HIV/AIDS: a systematic review in five European countries

dc.contributor.author
Trapero-Bertran, Marta
dc.contributor.author
Oliva-Moreno, Juan
dc.date.accessioned
2025-05-20T00:01:35Z
dc.date.available
2025-05-20T00:01:35Z
dc.date.issued
2014-09-16
dc.identifier.citation
Trapero Bertran, Marta; Oliva Moreno, Juan. «Economic impact of HIV/AIDS: a systematic review in five European countries». Health Economics Review, 2014, vol. 4, art. 15. Disponible en: <https://healtheconomicsreview.biomedcentral.com/articles/10.1186/s13561-014-0015-5>. Fecha de acceso: 09 dic. 2019. DOI: 10.1186/s13561-014-0015-5
dc.identifier.issn
2191-1991
dc.identifier.uri
http://hdl.handle.net/20.500.12328/1384
dc.description
The authors would like to acknowledge the support received from the research project ECON2013-48217-C2-2-R “Impacto económico, sanitario y social de las enfermedades y los problemas de salud: información y herramientas para la evaluacion de políticas públicas.
dc.description.abstract
The HIV/AIDS disease represent a priority for all health authorities in all countries and it also represents serious added socioeconomic problems for societies over the world. The aim of this paper is to analize the economic impact associated to the HIV/AIDS in an European context. We conducted a systematic literature review for five different countries (France, Germany, Italy, Spain and United Kingdom) and searched five databases. Three types of analyses were undertaken: descriptive statistics; quantitative analysis to calculate mean costs; and comparison across countries. 26 papers were included in this study containing seventy-six cost estimates. Most of the studies analyzed the health care cost of treatment of HIV/AIDS. Only 50% of the cost estimates provided mean lymphocyte count describing the patients’ disease stage. Approximately thirty percent of cost estimates did not indicate the developmental stage of the illness in the patients included. There is a high degree of variability in the estimated annual cost per patient of the treatments across countries. There is also a great disparity in total healh care costs for patients with lymphocyte counts between 200CD4+/mm3 and 500 CD4/mm3, although the reason of variation is unclear. In spite of the potential economic impact in terms of productivity losses and cost of formal and informal care, few studies have set out to estimate the non-medical costs of HIV/AIDS in the countries selected. Another important result is that, despite the low HIV/AIDS prevalence, its economic burden is very relevant in terms of the total health care costs in this five countries. This study also shows that there are relatively few studies of HIV costs in European countries compared to other diseases. Finally, we conclude that the methodology used in many of the studies carried out leaves ample room for improvement and that there is a need for these studies to reflect the economic impact of HIV/AIDS beyond health care including other components of social burden.
dc.format.extent
16
dc.language.iso
eng
dc.publisher
SpringerOpen
dc.relation.ispartof
Health Economics Review
dc.relation.ispartofseries
4;15
dc.rights
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights
Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.uri
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject
Cost
dc.subject
VIH (Virus)
dc.subject
Costes
dc.subject
Europa
dc.subject
HIV (Viruses)
dc.subject
Europe
dc.title
Economic impact of HIV/AIDS: a systematic review in five European countries
dc.type
info:eu-repo/semantics/article
dc.subject.udc
33
dc.subject.udc
61
dc.description.version
info:eu-repo/semantics/acceptedVersion
dc.embargo.terms
cap
dc.relation.projectID
info:eu-repo/grantAgreement/ES/ECON2013-48217-C2-2-R
dc.identifier.doi
https://doi.org/10.1186/s13561-014-0015-5


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)